Figure 2.
Figure 2. Study design of ongoing phase 3 IFM/HOVON MMY-3006 trial. Dara indicates daratumumab; and MEL 200, 200 mg/m2 melphalan.

Study design of ongoing phase 3 IFM/HOVON MMY-3006 trial. Dara indicates daratumumab; and MEL 200, 200 mg/m2 melphalan.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal